Renaissance Technologies
TRDA icon

Renaissance Technologies’s Entrada Therapeutics TRDA Stock Holding History

Renaissance Technologies’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.41M Sell
191,000
-11,084
-5% -$106K ﹤0.01% 2157
2026
Q1 		$2.55M Sell
202,084
-50,551
-20% -$579K ﹤0.01% 1755
2025
Q4 		$2.6M Sell
252,635
-341,665
-57% -$2.88M ﹤0.01% 1703
2025
Q3 		$3.45M Buy
594,300
+214,800
+57% +$1.26M ﹤0.01% 1703
2025
Q2 		$2.55M Buy
379,500
+51,015
+16% +$410K ﹤0.01% 1961
2025
Q1 		$2.97M Buy
328,485
+162,285
+98% +$2.02M ﹤0.01% 1751
2024
Q4 		$2.87M Buy
166,200
+72,400
+77% +$1.31M ﹤0.01% 1807
2024
Q3 		$1.5M Buy
93,800
+49,200
+110% +$775K ﹤0.01% 2202
2024
Q2 		$636K Buy
+44,600
New +$634K ﹤0.01% 2583
2022
Q2 		– Sell
-11,800
Closed -$111K – 4579
2022
Q1 		$111K Sell
11,800
-1,773
-13% -$19K ﹤0.01% 3774
2021
Q4 		$232K Buy
+13,573
New +$329K ﹤0.01% 3455

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Renaissance Technologies's TRDA Position: Q2 2026 in Review

Renaissance Technologies reduced its Entrada Therapeutics (TRDA) stake by 5.5% in Q2 2026, selling an estimated $106K and leaving 191,000 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2157.

Renaissance Technologies first reported a position in TRDA in Q4 2021 and has held it in 11 quarters since. The position peaked at $3.45M in Q3 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Renaissance Technologies held 191,000 shares of Entrada Therapeutics worth $1.41M as of Q2 2026.
  • Renaissance Technologies sold 11,084 Entrada Therapeutics shares in Q2 2026, an estimated $106K.
  • Entrada Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2157 holding.
  • Renaissance Technologies first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • Renaissance Technologies's Entrada Therapeutics position peaked at $3.45M in Q3 2025.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.